Atai Life Sciences (Nasdaq:ATAI) recently announced positive results from a Phase 1 study testing KUR-101 for opioid use disorder. KUR-101 is an oral formulation of the kratom alkaloid mitragynine. Atai subsidiary Kures is leading the effort to test the potential of mitragynine, which acts as a partial mu-opioid receptor agonist. Kratom itself is a source of controversy.…
FDA seeks comments on psychotropic substances, including kratom
The FDA has announced that it is looking for feedback on seven drugs, including kratom (mitragynine, 7-hydroxymitragynine), a popular recreational drug that remains legal at the federal level. FDA has warned consumers not to use kratom, which targets opioid receptors in the brain. There are no FDA-approved uses for the psychotropic herbal extract. WHO had reached…